Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

2 Jun 2023

Beckley Waves Establishes Psychedelics Ethics Council to Guide Industry Standards and Best Practices

The New Ethics Council will Work Alongside Beckley Waves to set the Standard for Sustainable and Ethical Operations in the Burgeoning Psychedelics Sector...

By Microdose NewsDesk

Breaking News

1 Jun 2023

Breaking News: Reunion Neuroscience Sold and Going Private

This morning we received news that Reunion Neuroscience has been sold to MPM BioImpact, a private biotechnology investment firm....

By Microdose NewsDesk

Breaking News

31 May 2023

Breaking News: Kentucky Commits $42 Million for Psychedelic Research

Attorney General for the US State of Kentucky, Daniel Cameron, announced that Kentucky will allocate $42 million for psychedelic research, specifically ibogaine for opioid addiction....

By Microdose NewsDesk

Finance

31 May 2023

Cybin Announces US$30M Capital Agreement

Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

26 May 2023

Small Pharma Expands Intellectual Property Portfolio

Small Pharma announces significant developments In Intellectual Property Portfolio...

By Microdose NewsDesk

Law & Politics

25 May 2023

Bill To Legalize Psychedelics Passes California Senate

The California Senate has passed a bill legalizing the possession of natural psychedelics....

By Microdose NewsDesk

Industry

24 May 2023

Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial

Cybin announced the first participants have been dosed with CYB004 in its three-part Phase 1 clinical trial...

By Microdose NewsDesk

Science

24 May 2023

New Study Shows Ketamine Improves Plasticity and Depression Results

A new study has shown that intravenous ketamine can improve depression symptoms in patients with treatment-resistant depression....

By Microdose NewsDesk

Breaking News

24 May 2023

MindBio Therapeutics Receives Approval for First-Ever Phase 2 Trial of LSD Microdosing

MindBio Therapeutics Ethics Approval for Landmark World First Phase 2 Clinical Trial of Take-Home LSD-Microdosing for Major Depressive Disorder...

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.